Clinical and Biological Database in Colon Cancer and Colic Tumors (BCBCOLON)
Primary Purpose
Cancer Colon
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Biological collection
Sponsored by
About this trial
This is an interventional other trial for Cancer Colon focused on measuring cancer, colon, tumor, colic
Eligibility Criteria
Inclusion Criteria:
- Patient undergoing colon cancer surgery (stage I, II, III and IV)
- Patient operated for liver or lung or peritoneal carcinomatosis metastases originating from colon cancer
- Patient operated for pre-neoplastic lesion (adenomatous polyp /villous adenoma polyp),
- Patient with familial polyposis eligible for colectomy
- Age > 18 years
- Signed informed consent
Exclusion Criteria:
- Patient not affiliated to Social Protection system
- Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
- Patient under guardianship
- Minor patient
Sites / Locations
- CHRU de MontpellierRecruiting
- Institut Régional du cancer de MontpellierRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Biological collection
Arm Description
For all the patients include in the study : samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections. In parallel to this biological collection, standardized clinical data will be entered into a database
Outcomes
Primary Outcome Measures
Number of clinical risk factors for colorectal cancer
Number of biological risk factors for colorectal cancer
Secondary Outcome Measures
Full Information
NCT ID
NCT03976960
First Posted
June 5, 2019
Last Updated
November 3, 2021
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
1. Study Identification
Unique Protocol Identification Number
NCT03976960
Brief Title
Clinical and Biological Database in Colon Cancer and Colic Tumors
Acronym
BCBCOLON
Official Title
Prospective, Multicenter, Clinical and Biological Database Set-up in Colon Cancer and Colic Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 19, 2018 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2030 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Developement of a clinical and biological database in colon cancer and colic tumors in order to better understand tumor invasion and metastatic scattering processes. The investigators hope that a better understanding of tumoral invasion process will lead to the discovery of new biomarkers and new drugs.
Detailed Description
As the second leading cause of cancer-related death in France, colorectal cancer is a major public health problem. Each year, 37 000 cases are newly diagnosed in France and 17 000 patients die of the disease.
Colorectal cancer is due to molecular and genetic damages involved in all tumorigenesis steps, transition from healthy tissue to adenoma and finally to invasive carcinoma stage. The investigators hope that a to better understand tumor invasion and metastatic scattering processes will allow therapeutic innovation and the emergence of new biomarkers.
However, the study of early tumorigenesis phases as well as advanced stages of the disease is currently limited due to a lack of tissue samples.
In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological collection dedicated to the tissular and blood samples of patients with colorectal cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer Colon
Keywords
cancer, colon, tumor, colic
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Biological collection
Arm Type
Experimental
Arm Description
For all the patients include in the study :
samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.
In parallel to this biological collection, standardized clinical data will be entered into a database
Intervention Type
Other
Intervention Name(s)
Biological collection
Intervention Description
The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
Primary Outcome Measure Information:
Title
Number of clinical risk factors for colorectal cancer
Time Frame
Until the study completion : 6 years
Title
Number of biological risk factors for colorectal cancer
Time Frame
Until the study completion : 6 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient undergoing colon cancer surgery (stage I, II, III and IV)
Patient operated for liver or lung or peritoneal carcinomatosis metastases originating from colon cancer
Patient operated for pre-neoplastic lesion (adenomatous polyp /villous adenoma polyp),
Patient with familial polyposis eligible for colectomy
Age > 18 years
Signed informed consent
Exclusion Criteria:
Patient not affiliated to Social Protection system
Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
Patient under guardianship
Minor patient
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Pierre BLEUSE, M.D
Phone
4 67 61 31 02
Ext
+ 33
Email
DRCI-icm105@icm.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ERIC ASSENAT, M.D
Organizational Affiliation
Institut régional du cancer de Montpellier
Official's Role
Study Chair
Facility Information:
Facility Name
CHRU de Montpellier
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Assénat, MD
Phone
467330137
Ext
+33
Email
e-assenat@chu-montpellier.fr
Facility Name
Institut Régional du cancer de Montpellier
City
Montpellier
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ERIC ASSENAT, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
https://www.google.com/search?client=firefox-b-d&sxsrf=ALeKk0251JuQRT2bZiWL8ut7KwGhX0TKeQ:1596454499279&q=Estimation+nationale+de+l%27incidence+et+de+la+mortalit%C3%A9+par+cancer+en+France+entre+1980+et+2012.+Partie+1-+Tumeurs+solides.+Traitement+:+INCA+2013.&spell=1&sa=X&ved=2ahUKEwj7lNG6-P7qAhVKxIUKHZeSCMMQBSgAegQICxAq&biw=1920&bih=1006
Description
National estimate of cancer incidence and mortality in France between 1980 and 2012.
Learn more about this trial
Clinical and Biological Database in Colon Cancer and Colic Tumors
We'll reach out to this number within 24 hrs